$NAMS
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Healthcare
Sector
Biotechnology
Industry
Michael Harvey Davidson Facp.
CEO
68
Employees
$29.62
Current Price
$3.93B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 6 | $11,277,048.16 | 372,805 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 16 | $38,211,395.05 | 1,168,286 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 30 | $46,681,401.91 | 1,427,051 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.43
ActualN/A
Revenue
Estimated$920.44K
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.40
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.40
Actual-$0.63
Miss
Revenue
Estimated$920.44K
Actual$32.00K
Miss
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: